N-3-[12-b]-3--4--5--45--1H--1- N-3-imidazo[12-b]pyridazin-3-ylethynyl-4-methylphenyl-5-phenyl-45-dihydro-1H-pyrazol-1-carboxamide derivatives and pharmaceutical composition for use in preventing or treating kinase-related disease
VORONOI CO., LTD.;보로노이바이오 주식회사;보로노이바이오 주식회사;보로노이 주식회사;VORONOIBIO INC.;보로노이 주식회사
发明人:
LI HUA,이화,JO SEOHYUN,조서현,DO WOOMI,도우미,KIM HYUNKYUNG,김현경,CHOI JIEUN,최지은,LEE SUNHWA,이선화,SON JUNG BEOM,손정범,KIM NAMDOO,김남두
申请号：
KR1020190081308
公开号：
KR1020200006495A
申请日:
2019.07.05
申请国别(地区):
KR
年份:
2020
代理人:
摘要：
An N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide derivative exhibits an excellent inhibitory activity against one or more kinases selected from the group consisting of ABL1, ABL2, AURKB, BRK, CDK11, CDK8, CDK9, CDKL2, CIT, DDR1, FLT3, FLT3, HIPK4, HUNK, JAK3, KIT, LOK, LTK, MET, MET, MLK2, MUSK, MYO3A, PAK3, PCTK3, PDGFRA, PDGFRB, RIPK1, TIE1, and ZAK, and thus can be used as a therapeutic agent for kinase-associated diseases.N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체는,ABL1, ABL2, AURKB, BRK, CDK11, CDK8, CDK9, CDKL2, CIT, DDR1, FLT3, FLT3, HIPK4, HUNK, JAK3, KIT, LOK, LTK, MET, MET, MLK2, MUSK, MYO3A, PAK3, PCTK3, PDGFRA, PDGFRB, RIPK1, TIE1 및 ZAK으로 이루어지는 군으로부터 선택되는 1종 이상의 키나아제에 대해 우수한 억제 활성을 나타내므로, 키나아제 관련 질환의 치료제로 사용 가능한 효과가 있다.
